Campaign marks new brand direction focused on lip health and product innovation
9 October 2013 | By Pfizer
The brand’s latest innovation provides eight hours of moisture and contains advanced ingredient...
List view / Grid view
News
Pfizer announces top-line results of the first two of Five Phase 3 clinical trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
Gilead to stop Phase 3 Study 116 of Idelalisib in chronic lymphocytic leukemia early because of positive risk benefit
9 October 2013 | By Gilead
"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."
Many adults aged 60-plus plan to take steps to avoid flu but not other potentially preventable diseases such as shingles
8 October 2013 | By Merck
The survey revealed the importance of physicians and pharmacists in encouraging vaccination...
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
Janssen acquires investigational NS5A inhibitor for the treatment of Hepatitis C from GlaxoSmithKline
8 October 2013 | By Janssen Pharmaceuticals, Inc
"We're excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs)...
Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)
8 October 2013 | By Johnson & Johnson
Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells...
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
8 October 2013 | By GlaxoSmithKline
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases...
Tecan Academy launched in Europe
8 October 2013 | By Tecan
Tecan announces the European launch of its Tecan Academy web-based training tool...
Ben Venue Laboratories, Inc. to cease production
7 October 2013 | By Boehringer Ingelheim Corp
Ben Venue Laboratories, Inc has decided to cease production by the end of 2013...
MedImmune Completes Acquisition of Amplimmune
7 October 2013 | By AstraZeneca
As previously announced, the acquisition bolsters MedImmune’s oncology pipeline...
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
Intel and Janssen Pharmaceutica to collaborate with imec and 5 Flemish universities to open ExaScience Life Lab
7 October 2013 | By Mengele PMC
Lab will allow development of even more powerful supercomputers for life sciences research...
Janssen launches new initiative to drive health policy debate
7 October 2013 | By Publicis Life Brands Resolute
Multi-stakeholder collaboration at the heart of Janssen Health Policy Centre...
European health R&D investments stagnate for the first time in history Private industry invests 29 bln € in health R&D, and public authorities 18 bln €
7 October 2013 | By Publicis Life Brands Resolute
New report presents unique statistics on health R&D in the European Union...
